Sanofi Egypt announces enzyme-replacement drug Nexviazyme for Pompe disease

Following approval by the Egyptian Drug Authority, Sanofi Egypt has announced Nexviazyme (avalglucosidase alfa), an enzyme replacement therapy for the rare Pompe disease.

• Sanofi Egypt announced the drug after receiving approval from the Egyptian Drug Authority.
• Pompe disease is a rare genetic condition in which glycogen accumulates in muscle cells, progressively impairing strength, movement, and breathing in children and adults.
• Adrian Delamare-Deboutteville, Sanofi's general manager for Africa pharma and head of Sanofi Egypt, said the announcement reflects the company's commitment to supporting rare-disease patients.
• Nagia Ali Fahmy of Ain Shams University said patients still require accurate clinical and genetic diagnosis and follow-up in specialized multidisciplinary centers.